At ONEtoONE, we advise healthcare and life sciences companies, shareholders and investors on M&A across providers, pharma, medtech and digital health. We bring deep understanding of clinical, regulatory and reimbursement dynamics together with a global network of strategic and financial buyers, turning sector momentum into concrete deal opportunities. Our work focuses on positioning each company effectively, identifying the right counterparties and executing with precision in a market shaped by consolidation, innovation and digital transformation.
We specialize in M&A across:
Healthcare’s inelastic demand makes it a safe-haven sector in M&A, with essential services generating the stable, recurring revenue that attracts buyers seeking resilience and capital preservation. ONEtoONE helps owners translate that defensive quality into strong valuations and competitive buyer interest.
Highly fragmented care markets create ideal conditions for buy-and-build, as firms consolidate practices and labs to gain scale and negotiating power with insurers. We help owners position as platforms or attractive add-ons and source the right counterparties.
Pharma and medtech firms use M&A as outsourced R&D, acquiring biotech companies with promising pipelines or IP. This “inorganic growth” helps replace revenues as patents expire and generics increase competition.
Healthcare M&A is accelerating around the integration of digital tools such as telemedicine, AI diagnostics and remote monitoring. These deals improve efficiency and clinical outcomes while enabling scalable care that reaches beyond physical facilities.
